357 patients with hip osteoarthritis were randomized to a single intraarticular injection of either hylan G-F 20 or placebo saline. Patients were assessed over 26-week follow-up for outcome on improvement in the first question of the WOMAC Pain subscale (WOMAC A1), response rate on the WOMAC A1 (minimum 2-pt improvement), the WOMAC Pain subscale overall, the WOMAC Function subscale, and the incidence of adverse events. Results at all timepoints to 26 weeks demonstrated no significant differences between groups in any of the aforementioned outcome measures.